Mark Crowther

67.2k total citations · 17 hit papers
584 papers, 40.0k citations indexed

About

Mark Crowther is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine and Hematology. According to data from OpenAlex, Mark Crowther has authored 584 papers receiving a total of 40.0k indexed citations (citations by other indexed papers that have themselves been cited), including 311 papers in Internal Medicine, 284 papers in Cardiology and Cardiovascular Medicine and 158 papers in Hematology. Recurrent topics in Mark Crowther's work include Venous Thromboembolism Diagnosis and Management (311 papers), Atrial Fibrillation Management and Outcomes (232 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (69 papers). Mark Crowther is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (311 papers), Atrial Fibrillation Management and Outcomes (232 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (69 papers). Mark Crowther collaborates with scholars based in Canada, United States and Italy. Mark Crowther's co-authors include Wendy Lim, Elie A. Akl, Elaine M. Hylek, Francesco Dentali, Walter Ageno, Clive Kearon, Gordon Guyatt, Susan R. Kahn, Philip S. Wells and David García and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Mark Crowther

561 papers receiving 38.6k citations

Hit Papers

Antithrombotic Therapy for VTE Disease 2003 2026 2010 2018 2012 2008 2011 2012 2012 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antithrombotic Therapy for VTE Disease
    2012 4.5k citations Philip S. Wells, Mark Crowther et al. CHEST Journal profile →
  2. Pharmacology and Management of the Vitamin K Antagonists
    2008 1.6k citations Elaine M. Hylek, Mark Crowther et al. CHEST Journal profile →
  3. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
    2011 1.3k citations Wendy Lim, Mark Crowther et al. profile →
  4. Executive Summary
    2012 1.1k citations Gordon Guyatt, Mark Crowther et al. CHEST Journal profile →
  5. Oral Anticoagulant Therapy
    2012 1.1k citations Walter Ageno, Alexander Gallus et al. CHEST Journal profile →
  6. Evidence-Based Management of Anticoagulant Therapy
    2012 887 citations Anne Holbrook, Daniel M. Witt et al. CHEST Journal profile →
  7. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
    2015 732 citations John T. Curnutte, Stuart J. Connolly et al. profile →
  8. Treatment and Prevention of Heparin-Induced Thrombocytopenia
    2012 660 citations Mark Crowther et al. CHEST Journal profile →
  9. A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome
    2003 591 citations Mark Crowther, David R. Anderson et al. profile →
  10. Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
    2003 544 citations David R. Anderson, Mark Crowther et al. profile →
  11. Acute Kidney Injury After Cardiac Surgery
    2009 524 citations Keyvan Karkouti, Duminda N. Wijeysundera et al. Circulation profile →
  12. Antiphospholipid syndrome
    2010 523 citations Guillermo Ruiz‐Irastorza, Mark Crowther et al. profile →
  13. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection
    2016 477 citations Mark Crowther et al. profile →
  14. Diagnosis of DVT
    2012 455 citations Philip S. Wells, Mark Crowther et al. CHEST Journal profile →
  15. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
    2018 329 citations Daniel M. Witt, Anne Holbrook et al. profile →
  16. Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
    2014 323 citations Mark Crowther et al. profile →
  17. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
    2019 214 citations Mark Crowther et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Crowther Canada 93 21.4k 19.7k 10.3k 9.2k 4.0k 584 40.0k
Clive Kearon Canada 66 26.6k 1.2× 20.1k 1.0× 9.7k 0.9× 5.9k 0.6× 3.5k 0.9× 230 33.5k
Sam Schulman Canada 69 21.5k 1.0× 21.5k 1.1× 7.1k 0.7× 7.7k 0.8× 3.6k 0.9× 501 34.5k
Jack Hirsh Canada 96 22.3k 1.0× 22.7k 1.2× 13.3k 1.3× 8.2k 0.9× 2.8k 0.7× 350 38.4k
John A. Heit United States 68 23.7k 1.1× 15.2k 0.8× 9.3k 0.9× 6.5k 0.7× 2.5k 0.6× 220 30.9k
Harry R. Büller Netherlands 92 24.6k 1.2× 18.6k 0.9× 8.6k 0.8× 8.2k 0.9× 3.5k 0.9× 450 35.7k
Samuel Z. Goldhaber United States 100 35.0k 1.6× 27.6k 1.4× 10.6k 1.0× 5.4k 0.6× 6.6k 1.7× 614 47.4k
Martin H. Prins Netherlands 90 19.9k 0.9× 17.7k 0.9× 8.9k 0.9× 6.8k 0.7× 2.9k 0.7× 384 34.7k
Frits R. Rosendaal Netherlands 101 15.7k 0.7× 11.3k 0.6× 6.6k 0.6× 18.9k 2.0× 3.2k 0.8× 806 41.4k
John W. Eikelboom Canada 94 18.4k 0.9× 35.1k 1.8× 9.4k 0.9× 4.0k 0.4× 5.6k 1.4× 670 47.6k
Michael Gent Canada 90 16.1k 0.8× 20.2k 1.0× 9.1k 0.9× 5.1k 0.5× 5.7k 1.4× 230 34.9k

Countries citing papers authored by Mark Crowther

Since Specialization
Citations

This map shows the geographic impact of Mark Crowther's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Crowther with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Crowther more than expected).

Fields of papers citing papers by Mark Crowther

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Crowther. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Crowther. The network helps show where Mark Crowther may publish in the future.

Co-authorship network of co-authors of Mark Crowther

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Crowther. A scholar is included among the top collaborators of Mark Crowther based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Crowther. Mark Crowther is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Allen, et al.. (2025). Andexanet alfa vs standard of care for factor Xa inhibitor-induced intracranial hemorrhage—a systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis. 9(7). 103201–103201.
2.
Salter, Brittany, Karen A. Moffat, Laurel Beckett, et al.. (2024). Evaluation of the MRX PT DOAC assay for detection of clinically relevant factor Xa inhibitor drug levels. Journal of Thrombosis and Haemostasis. 23(3). 989–996.
3.
Crowther, Mark & Doruk Erkan. (2023). A new approach to antiphospholipid antibody syndrome. Research and Practice in Thrombosis and Haemostasis. 7(7). 102226–102226.
4.
Demchuk, Andrew M., Patrick Yue, Elena Zotova, et al.. (2021). Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke. 52(6). 2096–2105. 43 indexed citations
5.
Harenberg, Job, Jan Beyer‐Westendorf, Mark Crowther, et al.. (2019). Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial. Thrombosis and Haemostasis. 120(1). 132–140. 25 indexed citations
6.
7.
Carrier, Marc, Judy Kovacs, Marc Rodger, et al.. (2017). Association between remote major venous thromboembolism risk factors and the risk of recurrence after a first unprovoked episode. Journal of Thrombosis and Haemostasis. 15(10). 1977–1980. 2 indexed citations
8.
Alzamil, Hana, et al.. (2017). Is low serum albumin level a significant predictor for the development of heparin-induced thrombocytopenia-thrombosis?. Annals of Hematology. 96(6). 1033–1036. 1 indexed citations
9.
Li, Guowei, Mitchell Levine, Gordon Guyatt, et al.. (2015). Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. Medicine. 94(36). e1479–e1479. 23 indexed citations
10.
Ageno, Walter, et al.. (2012). Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis. CHEST Journal. 141. 49 indexed citations
11.
Karkouti, Keyvan, Duminda N. Wijeysundera, Terrence M. Yau, et al.. (2012). Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection. Anesthesiology. 116(3). 613–621. 71 indexed citations
12.
Dentali, Francesco, Nicoletta Riva, Mark Crowther, et al.. (2012). Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation. Circulation. 126(20). 2381–2391. 288 indexed citations
13.
14.
Crowther, Mark, et al.. (2011). Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. Journal of Thrombosis and Thrombolysis. 31(3). 249–258. 34 indexed citations
15.
Pai, Menaka & Mark Crowther. (2011). Neutralization of Heparin Activity. Handbook of experimental pharmacology. 265–277. 30 indexed citations
16.
Ribic, Christine, et al.. (2009). Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review. Journal of Critical Care. 24(2). 197–205. 30 indexed citations
17.
Crowther, Mark & Simon Bell. (2007). Neuropathic shoulder in syringomyelia treated with resurfacing arthroplasty of humeral head and soft-tissue lining of glenoid: A case report. Journal of Shoulder and Elbow Surgery. 16(6). e38–e40. 19 indexed citations
18.
Ng, Heng Joo & Mark Crowther. (2006). Azathioprine and inhibition of the anticoagulant effect of warfarin: Evidence from a case report and a literature review. ˜The œAmerican journal of geriatric pharmacotherapy. 4(1). 75–77. 18 indexed citations
19.
Brimble, K. Scott, et al.. (2006). Effect of chronic kidney disease on red blood cell rheology.. PubMed. 34(3). 411–20. 28 indexed citations
20.
Crowther, Mark, Andrew Pilling, & Kelly P. Owen. (1997). The evaluation of glycofurol as a vehicle for use in toxicity studies. Human & Experimental Toxicology. 16(7). 406. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Clive Kearon Breakdown of academic impact, for papers by Sam Schulman Breakdown of academic impact, for papers by Jack Hirsh Breakdown of academic impact, for papers by John A. Heit Breakdown of academic impact, for papers by Harry R. Büller Breakdown of academic impact, for papers by Samuel Z. Goldhaber Breakdown of academic impact, for papers by Martin H. Prins Breakdown of academic impact, for papers by Frits R. Rosendaal Breakdown of academic impact, for papers by John W. Eikelboom Breakdown of academic impact, for papers by Michael Gent
Rankless by CCL
2026